Metatron Hunter: Diagnosing Gastric and Colon Cancer

The Non-Linear Diagnostics (NLS) method using the Metatron Hunter has recently been actively implemented across many medical institutions. The most tangible results have been achieved by utilizing NLS for ongoing clinical monitoring. Through its continued development, this method has become a crucial tool for diagnosing and monitoring a wide range of digestive tract disorders; it facilitates a rapid, detailed understanding of lesions and their patterns while aiding in the assessment of treatment efficacy. These findings emerged from our studies on various conditions, including gastroduodenal ulcers, chronic gastritis, and both benign and malignant tumors of the stomach and colon. The specific operational characteristics of Russian medical and clinical facilities have enabled the widespread use of NLS methodology, not only for diagnosing symptomatic cases but also for monitoring the effects of medication. Importantly, the speed and cost-effectiveness of the procedure make NLS diagnostics accessible to a large number of patients. Physicians can now evaluate patients for potential abnormalities that can only be verified through NLS—specifically, patients with precancerous conditions or mucosal disorders in the upper and/or lower digestive tract, as well as those harboring tumors that remain in a latent stage.

Data obtained by medical experts—based on annual NLS diagnostic studies involving thousands of cases—indicate that the frequency of localized or diffuse changes (such as chronic atrophic gastritis) in patients over the age of 50 ranges from 30% to 40%. Spectral analysis of focal changes in the gastric mucosa frequently reveals signs of conditions such as intestinal metaplasia and epithelial dysplasia. NLS analysis detects gastric ulcers in approximately 5% of cases, gastric polyps in 7%, and colon polyps in 45%. Consequently, based solely on NLS results (and without considering other risk factors), a significant proportion of patients across all age groups appear to fall into the category requiring ongoing monitoring due to the potential risk of gastric cancer (GC) or colon cancer (CC). Two critical factors are known to be essential for the diagnosis of malignancies: the quality of clinical and diagnostic techniques, and the specific patterns of disease progression—which effectively determine the dynamics of the disease's advancement. Even when considering the capabilities and working conditions of medical facilities, the diagnostic data for gastric and colon cancers can be regarded as optimal to a certain extent. This implies that, while the disease is potentially detectable in all patients during medical monitoring (addressing what is effectively 60% of the challenge), cases at the initial stage are identified in only 40% of patients. An analysis of the causes behind delayed diagnoses suggests that such cases could be prevented through improved organizational and procedural practices.

Consequently, the Metatron Hunter NLS system can be considered a suitable method for diagnosing gastric and colon cancers. While interpreting NLS data presents challenges—particularly regarding the initial stages—the long-term frequency of disease detection depends largely on the physician's diligence in using spectral analysis to verify any focal changes in the mucosa.